Latest news with #AstranaHealth
Yahoo
20 hours ago
- Business
- Yahoo
Astrana Health, Inc. Schedules 2025 Second Quarter Financial Results Release and Conference Call
ALHAMBRA, Calif., July 22, 2025 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced that it will release financial results for the second quarter ended June 30, 2025, after the close of the stock market on Thursday, August 7, 2025. The Company will discuss those results on a conference call at 2:30 p.m. PT/5:30 p.m. ET that same day. Astrana Health Logo (PRNewsfoto/Astrana Health, Inc.) Participant Dial-in Numbers: 877-858-9810 / +1 201-689-8517 To access the call, please dial in approximately five minutes before start time. An accompanying slide presentation will be available in PDF format on the "IR Calendar" page of the Company's website ( after issuance of the earnings release. Webcast The call will also be available via online webcast at: Those who are unable to attend the live conference call may access the recording at the above webcast link, which will be made available shortly after the conclusion of the call. About Astrana Health, Inc. Astrana Health is a physician-centric, AI-powered healthcare company committed to delivering high-quality, patient-centered care. Built from the physician's perspective, Astrana combines its scalable care delivery infrastructure, proprietary technology platform, and aligned provider networks to enable proactive, preventive care at scale - improving patient outcomes, enhancing patient experiences, supporting provider well-being, and driving greater value across the healthcare system. Today, Astrana supports more than 20,000 providers and over 1.6 million patients in value-based care arrangements through its affiliated provider networks, management services organization, and integrated care delivery clinics spanning primary, specialty, and ancillary care. Together, Astrana is building the healthcare system we all deserve - one that delivers better care, better experiences, and better outcomes for all. For more information, visit FOR MORE INFORMATION, PLEASE CONTACT: Grant Hesser, Investor Relations Cision View original content to download multimedia: SOURCE Astrana Health, Inc.
Yahoo
11-07-2025
- Business
- Yahoo
Zacks.com featured highlights Astrana Health, KT, Upbound, Noah Holdings and DXP Enterprises
Chicago, IL – July 11, 2025 – The stocks in this week's article are Astrana Health, Inc. ASTH, KT Corp. KT, Upbound Group, Inc. UPBD, Noah Holdings Ltd. NOAH and DXP Enterprises, Inc. DXPE. Investors are typically fixated on the price-to-earnings (P/E) strategy while seeking stocks trading at attractive prices. This straightforward, easy-to-calculate ratio is the most preferred among all valuation metrics in the investment toolkit for working out the fair market value of a stock. But even this ubiquitously used valuation metric is not without its pitfalls. Although P/E is the most popular valuation metric, a more complicated multiple called EV-to-EBITDA works even better. Often considered a better alternative to P/E, it gives the true picture of a company's valuation and earnings potential, and has a more complete approach to valuation. While P/E considers a firm's equity portion, EV-to-EBITDA determines its total value. Astrana Health, Inc., KT Corp., Upbound Group, Inc., Noah Holdings Ltd. and DXP Enterprises, Inc. are some stocks with impressive EV-to-EBITDA ratios. Here's Why EV-to-EBITDA is a Better Option Also referred to as enterprise multiple, EV-to-EBITDA is the enterprise value (EV) of a stock divided by its earnings before interest, taxes, depreciation and amortization (EBITDA). EV is the sum of a company's market capitalization, its debt and preferred stock minus cash and cash equivalents. In essence, it is the entire value of a company. EBITDA, the other element, gives a clearer picture of a company's profitability by removing the impact of non-cash expenses like depreciation and amortization that dampen net earnings. It is also often used as a proxy for cash flows. Typically, the lower the EV-to-EBITDA ratio, the more enticing it is. A low EV-to-EBITDA ratio could indicate that a stock is undervalued. Unlike the P/E ratio, EV-to-EBITDA takes debt on a company's balance sheet into account. For this reason, it is typically used to value acquisition targets. The ratio shows the amount of debt that the acquirer has to bear. Stocks flaunting a low EV-to-EBITDA multiple could be seen as attractive takeover candidates. P/E can't be used to value a loss-making firm. A firm's earnings are also subject to accounting estimates and management manipulation. In contrast, EV-to-EBITDA is harder to manipulate and can be used to value companies that have negative net earnings but are positive on the EBITDA front. EV-to-EBITDA is also a useful tool in measuring the value of firms that are highly leveraged and have a high degree of depreciation. It can also be used to compare companies with different levels of debt. EV-to-EBITDA is not devoid of limitations and alone cannot conclusively determine a stock's inherent potential and future performance. The multiple varies across industries and is usually not appropriate while comparing stocks in different industries, given their diverse capital expenditure requirements. Thus, instead of just relying on EV-to-EBITDA, you can club it with the other major ratios, such as price-to-book (P/B), P/E and price-to-sales (P/S) to achieve the desired results. Here are our five picks out of the 12 stocks that passed the screen: Astrana Health is a physician-centric healthcare company committed to delivering high-quality, patient-centered care. This Zacks Rank #1 stock has a Value Score of A. Astrana Health has an expected earnings growth rate of 76.7% for 2025. The Zacks Consensus Estimate for ASTH's 2025 earnings has moved up 16.9% over the past 60 days. KT Corporation is the biggest telecommunications operator in the Republic of Korea. This Zacks Rank #2 stock has a Value Score of A. KT has an expected earnings growth rate of 280% for 2025. The Zacks Consensus Estimate for KT's 2025 earnings has been revised 2.3% upward over the past 60 days. Upbound Group is a leading lease-to-own provider with operations in the United States, Puerto Rico and Mexico. This Zacks Rank #2 firm has a Value Score of A. Upbound Group has an expected year-over-year earnings growth rate of 9.1% for 2025. The consensus estimate for UPBD's 2025 earnings has been revised 0.5% upward over the past 60 days. Noah Holdings is a leading wealth management service provider in China. NOAH, a Zacks Rank #2 stock, has a Value Score of A. Noah Holdings has an expected year-over-year earnings growth rate of 28% for 2025. The consensus estimate for NOAH's 2025 earnings has been revised 4.6% upward over the past 60 days. DXP Enterprises provides innovative pumping solutions, supply-chain services, and maintenance, repair, operating and production services. This Zacks Rank #2 firm has a Value Score of B. DXP Enterprises has an expected earnings growth rate of 17.5% for 2025. The Zacks Consensus Estimate for DXPE's 2025 earnings has been revised 0.4% higher over the past 60 days. You can get the rest of the stocks on this list by signing up now for your 2-week free trial to the Research Wizard and start using this screen in your own trading. Further, you can also create your own strategies and test them first before taking the investment plunge. The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out. Click here to sign up for a free trial to the Research Wizard today. For the rest of this Screen of the Week article please visit at: Follow us on Twitter: Join us on Facebook: Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Contact: Jim Giaquinto Company: Phone: 312-265-9268 Email: pr@ Visit: provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report KT Corporation (KT) : Free Stock Analysis Report DXP Enterprises, Inc. (DXPE) : Free Stock Analysis Report Noah Holdings Ltd. (NOAH) : Free Stock Analysis Report Upbound Group, Inc. (UPBD) : Free Stock Analysis Report Astrana Health, Inc. (ASTH) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
04-07-2025
- Business
- Yahoo
Top Growth Stocks With High Insider Ownership July 2025
The United States market has shown positive momentum recently, with a 2.1% increase over the last week and a 14% rise in the past year, as all sectors have gained ground. In light of these strong market conditions and an anticipated annual earnings growth of 15%, stocks with high insider ownership can be particularly appealing as they often indicate confidence from those closest to the company's operations and potential for sustained growth. Name Insider Ownership Earnings Growth Zapp Electric Vehicles Group (ZAPP.F) 16.1% 170.8% Super Micro Computer (SMCI) 13.9% 39.1% Ryan Specialty Holdings (RYAN) 15.6% 95.3% Prairie Operating (PROP) 34.6% 92.4% FTC Solar (FTCI) 28.3% 62.5% Enovix (ENVX) 12.1% 58.4% Credo Technology Group Holding (CRDO) 11.9% 45% Atour Lifestyle Holdings (ATAT) 21.8% 23.7% Astera Labs (ALAB) 13.1% 44.4% ARS Pharmaceuticals (SPRY) 14.3% 63.1% Click here to see the full list of 188 stocks from our Fast Growing US Companies With High Insider Ownership screener. Underneath we present a selection of stocks filtered out by our screen. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Astrana Health, Inc. is a healthcare management company offering medical care services in the United States with a market cap of approximately $1.26 billion. Operations: Astrana Health generates revenue through its segments: Care Delivery ($139.34 million), Care Partners ($2.17 billion), and Care Enablement ($161.74 million). Insider Ownership: 12.5% Revenue Growth Forecast: 15.1% p.a. Astrana Health's revenue is forecast to grow at 15.1% annually, outpacing the US market average, while earnings are expected to rise significantly at 30.8% per year. Despite recent index exclusions and a drop in profit margins, the company remains undervalued by 81.7%. Recent leadership changes aim to bolster its AI-enabled care platform as it scales nationally. A completed share buyback program signals confidence amidst these strategic shifts and financial challenges. Click to explore a detailed breakdown of our findings in Astrana Health's earnings growth report. Insights from our recent valuation report point to the potential undervaluation of Astrana Health shares in the market. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Youdao, Inc. is an internet technology company offering online services in content, community, communication, and commerce sectors in China with a market cap of approximately $1.03 billion. Operations: The company's revenue is primarily derived from Learning Services (CN¥2.63 billion), Online Marketing Services (CN¥1.99 billion), and Smart Devices (CN¥912.97 million). Insider Ownership: 20.4% Revenue Growth Forecast: 11.3% p.a. Youdao's revenue is projected to grow at 11.3% annually, surpassing the US market rate, while its earnings are expected to rise significantly at 35.7% per year. The company recently became profitable but faces challenges with negative shareholders' equity and debt coverage by operating cash flow. Despite no recent insider trading activity, Youdao completed a substantial share buyback of 6.19%, reflecting confidence in its growth trajectory amidst financial hurdles. Delve into the full analysis future growth report here for a deeper understanding of Youdao. Our valuation report here indicates Youdao may be overvalued. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Perfect Corp. is an artificial intelligence software as a service company offering AI and AR-powered solutions for the beauty, fashion, and skincare industries globally, with a market cap of $257.68 million. Operations: The company's revenue primarily comes from its Internet Software & Services segment, generating $61.93 million. Insider Ownership: 23% Revenue Growth Forecast: 12.9% p.a. Perfect Corp. is poised for growth with forecasted annual earnings increases of 22.1%, outpacing the US market. Recent strategic partnerships, like its integration with NVIDIA, enhance its AI and AR capabilities, transforming consumer experiences in beauty and fashion through virtual try-ons and AI-driven recommendations. Despite limited insider trading data, Perfect Corp.'s innovative solutions are expected to drive revenue growth at 12.9% annually, supported by recent product launches that address online shopping challenges effectively. Dive into the specifics of Perfect here with our thorough growth forecast report. Our comprehensive valuation report raises the possibility that Perfect is priced higher than what may be justified by its financials. Access the full spectrum of 188 Fast Growing US Companies With High Insider Ownership by clicking on this link. Contemplating Other Strategies? Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 24 best rare earth metal stocks of the very few that mine this essential strategic resource. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years. Companies discussed in this article include ASTH DAO and PERF. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
Yahoo
04-07-2025
- Business
- Yahoo
Astrana Health completes acquisition of Prospect Health for $708m
US-based Astrana Health has closed its acquisition of Prospect Health, a care delivery network, for a total purchase price of $708m. With a network of more than 11,000 providers, Prospet Health offers coordinated care to approximately 600,000 members. The network covers various states in the US, including Arizona, Rhode Island, Southern California, and Texas, serving Medicaid, Medicare Advantage, and Commercial business lines. Prospect Health's operations include a health plan, a management services organisation, a speciality pharmacy, and an acute care hospital. The acquisition price reflects a decrease from the initially stated $745m in November 2024. Astrana president and CEO Brandon Sim said: "We are excited to welcome Prospect Health's physicians, providers, and team members to Astrana Health. "Together, we will further accelerate our mission to drive consistent, coordinated, high-quality patient outcomes at scale, ultimately driving greater value across the healthcare ecosystem." Astrana projects that Prospect Health will contribute a total revenue of approximately $1.2bn and $81m in adjusted EBITDA annually. In addition, Astrana anticipates achieving $12m to $15m of synergies within the next one to one-and-a-half years. The company has updated its 2025 full-year guidance to a revenue range of $3.1bn to $3.3bn and adjusted EBITDA between $215m and $225m, considering Prospect Health's half-year contribution. Following the transaction, Astrana's net debt is expected to be approximately $700m. The company's management is focused on lessening the net leverage ratio to below 2.5 times within the next one to one-and-a-half years. Truist Securities led a consortium of banks that offered the term loan for the purchase. J P Morgan acted as the exclusive financial adviser to Astrana during the transaction. The acquisition follows Astrana's previous acquisition of Collaborative Health Systems in October last year, which also aimed to broaden its care delivery capabilities. "Astrana Health completes acquisition of Prospect Health for $708m" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30-06-2025
- Business
- Yahoo
5 Must-Read Analyst Questions From Astrana Health's Q1 Earnings Call
Astrana Health's first quarter results for 2025 were met with a negative market reaction, with revenue growth driven by its Care Partners segment and progress in full-risk contracts. However, management acknowledged that the quarter's performance was tempered by lower-than-expected revenue and compressed operating margins. CEO Brandon Sim pointed to the flu season and higher emergency room and lab utilization in Medicaid as factors impacting costs, while also highlighting ongoing investments in technology and integration. Sim stated, 'Margins were moderated by planned ongoing investments in growth integration technology, as well as by revenue growth in areas with lower near-term margin profiles.' Is now the time to buy ASTH? Find out in our full research report (it's free). Revenue: $620.4 million vs analyst estimates of $636.2 million (53.4% year-on-year growth, 2.5% miss) Adjusted EPS: $0.34 vs analyst estimates of $0.33 (in line) Adjusted EBITDA: $36.39 million vs analyst estimates of $35.7 million (5.9% margin, 1.9% beat) The company reconfirmed its revenue guidance for the full year of $2.6 billion at the midpoint EBITDA guidance for the full year is $180 million at the midpoint, below analyst estimates of $181.2 million Operating Margin: 3.3%, down from 7.5% in the same quarter last year Market Capitalization: $1.23 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Ryan Daniels (William Blair) asked about remaining milestones for CHS integration. CEO Brandon Sim explained integration is complete, but further implementation of the care model should drive margin improvements over time. Michael Ha (Baird) pressed on the seasonality and drivers behind the lighter revenue outlook for next quarter. Sim attributed this to Medicaid volatility and full-risk conversions being weighted toward the second half of the year. Jack Slevin (Jefferies) questioned Astrana's confidence in leveraging favorable Medicare Advantage rates. Sim responded that while the rate update was anticipated, its exact financial impact will become clearer as more details emerge. Jailendra Singh (Truist Securities) asked about profitability in the ACO REACH program and the impact of recent risk adjustment changes. Sim shared that the company absorbed a modest drag from retroactive adjustments, offset by other risk-management strategies. Brooks O'Neil (Lake Street Capital Markets) probed on organizational stress from rapid growth and integration. Sim acknowledged the challenges of scaling rapidly, emphasizing ongoing focus on integration and cultural cohesion. In the upcoming quarters, the StockStory team will be monitoring (1) the pace and effectiveness of integrating Prospect Health and realizing promised synergies, (2) the continued conversion of members to full-risk contracts and resulting margin trends, and (3) the outcome of Medicaid contract renewals and regulatory developments in key states. Progress in leadership-driven data and technology initiatives will also be a key signpost for sustainable growth. Astrana Health currently trades at $24.73, down from $33.40 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it's free). The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
